DCPH Deciphera Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DCPH

Price (delayed)

$12.495

Market cap

$984.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.27

Enterprise value

$931M

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase ...

Highlights
The company's EPS rose by 47% YoY
Deciphera Pharmaceuticals's revenue has increased by 32% YoY and by 4.2% QoQ
The net income has grown by 28% YoY but it has contracted by 3% from the previous quarter
Deciphera Pharmaceuticals's quick ratio has decreased by 21% YoY and by 14% from the previous quarter
Deciphera Pharmaceuticals's equity has decreased by 8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.deciphera.com
Peers: OMGA

Key stats

What are the main financial stats of DCPH
Market
Shares outstanding
78.82M
Market cap
$984.87M
Enterprise value
$931M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.43
Price to sales (P/S)
7.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.46
Earnings
Revenue
$144.07M
EBIT
-$186.43M
EBITDA
-$179.52M
Free cash flow
-$145.27M
Per share
EPS
-$2.27
Free cash flow per share
-$1.71
Book value per share
$5.15
Revenue per share
$1.69
TBVPS
$5.99
Balance sheet
Total assets
$509.62M
Total liabilities
$105.19M
Debt
$27.52M
Equity
$404.43M
Working capital
$324.02M
Liquidity
Debt to equity
0.07
Current ratio
5
Quick ratio
4.34
Net debt/EBITDA
0.3
Margins
EBITDA margin
-124.6%
Gross margin
95%
Net margin
-129.9%
Operating margin
-137.5%
Efficiency
Return on assets
-37.6%
Return on equity
-48%
Return on invested capital
-52%
Return on capital employed
-43.5%
Return on sales
-129.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DCPH stock price

How has the Deciphera Pharmaceuticals stock price performed over time
Intraday
-0.28%
1 week
-10.81%
1 month
-13.29%
1 year
-28.92%
YTD
-23.76%
QTD
-11.26%

Financial performance

How have Deciphera Pharmaceuticals's revenue and profit performed over time
Revenue
$144.07M
Gross profit
$136.82M
Operating income
-$198.07M
Net income
-$187.15M
Gross margin
95%
Net margin
-129.9%
The net margin has increased by 45% year-on-year
The company's operating margin rose by 42% YoY
Deciphera Pharmaceuticals's revenue has increased by 32% YoY and by 4.2% QoQ
The gross profit is up by 30% year-on-year and by 6% since the previous quarter

Growth

What is Deciphera Pharmaceuticals's growth rate over time

Valuation

What is Deciphera Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.43
P/S
7.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.46
The company's EPS rose by 47% YoY
The P/B is 36% below the 5-year quarterly average of 3.8 and 19% below the last 4 quarters average of 3.0
Deciphera Pharmaceuticals's equity has decreased by 8% QoQ
DCPH's price to sales (P/S) is 89% less than its 5-year quarterly average of 64.9 and 24% less than its last 4 quarters average of 9.7
Deciphera Pharmaceuticals's revenue has increased by 32% YoY and by 4.2% QoQ

Efficiency

How efficient is Deciphera Pharmaceuticals business performance
The company's return on sales rose by 45% YoY
Deciphera Pharmaceuticals's return on invested capital has increased by 37% YoY
The return on equity has grown by 37% year-on-year but it has declined by 3% since the previous quarter
The ROA has grown by 34% YoY but it has contracted by 2.7% from the previous quarter

Dividends

What is DCPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DCPH.

Financial health

How did Deciphera Pharmaceuticals financials performed over time
Deciphera Pharmaceuticals's quick ratio has decreased by 21% YoY and by 14% from the previous quarter
Deciphera Pharmaceuticals's current ratio has decreased by 17% YoY and by 12% QoQ
The debt is 93% smaller than the equity
DCPH's debt to equity is up by 17% from the previous quarter but it is down by 13% YoY
The debt has declined by 10% year-on-year and by 2.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.